(RTTNews) - Grifols S.A. (GRFS) on Tuesday reported higher profit for the first half of 2026, supported by growth in its Biopharma business. The company also reaffirmed its full-year guidance...
Nasdaq News: Markets
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
ADMA shares rebound 13.5% in a month after a steep decline, even as lowered 2026 guidance and IG market competition continue to weigh on sentiment.
Zacks
Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo
Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo...
Yahoo! Finance: News
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
ADMA faces IG pricing pressure and reduced 2026 guidance, but Asceniv demand remains strong amid resilient patient utilization.
Zacks
Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026?
ADMA cuts 2026 guidance after weak Bivigam sales and IG market pressure weigh on revenues amid rising competition and order volatility.
Zacks
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
ADMA shares plunge after the company cuts 2026 guidance, citing pricing pressure, rising competition and elevated IG channel inventories.
Zacks
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
ADMA stock in focus after FDA expands Asceniv's label to younger patients, boosting market reach and growth outlook amid rising demand.
Zacks
Wall Street Zen Downgrades Grifols (NASDAQ:GRFS) to Hold
Wall Street Zen cut shares of Grifols from a "buy" rating to a "hold" rating in a research report on Saturday...
MarketBeat
Grifols (GRFS) to Release Earnings on Thursday
Grifols (NASDAQ:GRFS) will be releasing its Q1 2026 earnings on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-grifols-sa-stock...